JEAN-FRANCOIS FORMELA

Profile

First Name

: JEAN-FRANCOIS

Middle Name

:

Last Name

: FORMELA

Related Companies
Titles
Company Name
Related People
DIRECTOR
ARCA BIOPHARMA, INC.
RICHARD B. BREWER, MICHAEL R. BRISTOW, ROBERT E. CONWAY, KATHRYN E. FALBERG, J. WILLIAM FREYTAG, LINDA GRAIS, LINDA S. GRAIS, THOMAS A. KEUER, TED W. LOVE, DAN J. MITCHELL, CHRISTOPHER D. OZEROFF, MARY K. PENDERGAST, BRIAN L. SELBY, BURTON E. SOBEL, PATRICK M. WHEELER, RAYMOND L. WOOSLEY, JOHN L. ZABRISKIE
DIRECTOR
RESOLVYX PHARMACEUTICALS, INC.
TIMOTHY J. BARBERICH, DOUGLAS COLE, PER GJORSTRUP, KEITH MANCHESTER, GEORGE M. MILNE, JR., JAMES NICHOLS, C. ERIC SCHWARTZ, PHILIP J. VICKERS, GREGORY WEINHOFF
DIRECTOR
HORIZON PHARMA, INC.
JEFFREY W. BIRD, HUBERT BIRNER, LOUIS C. BOCK, ROBERT DE VAERE, MICHAEL GREY, JEFF HIMAWAN, PETER JOHANN, RONALD PAULI, GINO SANTINI, TIMOTHY P. WALBERT
DIRECTOR
ANNOVATION BIOPHARMA, INC.
NICHOLAS BARKER, CARL BERKE, JASON CAMPAGNA, DAVID GRAYZEL, ANKIT MAHADEVIA, DOUGLAS RAINES
DIRECTOR
ARTEAUS THERAPEUTICS, LLC
JEAN-FRANCOIS FROMELA, DAVID GRAYZEL, THOMAS SCHUETZ
DIRECTOR
COSTIM PHARMACEUTICALS INC.
LUKE EVNIN, ROGER KITTERMAN, ROBERT MILLMAN, MARIAN NAKADA, JOSH RESNICK, KAZUMI SHIOSAKI
DIRECTOR
CALORICS, INC.
KEVIN BITTERMAN, BARRY BURGDORF, ALAN CRANE, JOHN CREECY, RAJEEV DADOO, PAUL FRIEDMAN, PAUL FRIEDMAN, M.D., BRIAN GALLAGHER, BRIAN GALLAGHER, PH.D., DAVID GOLDFARB, THOMAS HUGHES, RICHARD LUNDBERG, RICK LUNDBERG, DAVID MADDEN, MARIAN NAKADA, MARIAN NAKADA, PH.D., VINZENZ PLOERER, GEORG VLASUK, GEORGE VLASUK, GEORGE P. VLASUK
DIRECTOR
NAVITOR PHARMACEUTICALS, INC.
KEVIN BITTERMAN, BARRY BURGDORF, ALAN CRANE, JOHN CREECY, RAJEEV DADOO, PAUL FRIEDMAN, PAUL FRIEDMAN, M.D., BRIAN GALLAGHER, BRIAN GALLAGHER, PH.D., DAVID GOLDFARB, THOMAS HUGHES, RICHARD LUNDBERG, RICK LUNDBERG, DAVID MADDEN, MARIAN NAKADA, MARIAN NAKADA, PH.D., VINZENZ PLOERER, GEORG VLASUK, GEORGE VLASUK, GEORGE P. VLASUK
DIRECTOR
INTELLIA THERAPEUTICS, INC.
NESSAN BERMINGHAM, CARL GORDON, RACHEL HAURWITZ, JOHN LEONARD, JOSE RIVERA
DIRECTOR
IFM THERAPEUTICS, INC.
GARY GLICK
DIRECTOR
SPERO THERAPEUTICS, LLC
CASPER BREUM, MILIND DESHPANDE, STEPHEN GARBACZ, VIKAS GOYAL, REZA HALSE, KAMAL HAMED, SCOTT JACKSON, TAMARA JOSEPH, TIMOTHY KEUTZER, CRISTINA LARKIN, ANKIT MAHADEVIA, DAVID MELNICK, JOHN C. POTTAGE, JR., SATYAVRAT SHUKLA, CYNTHIA SMITH, FRANK E. THOMAS, KATHLEEN TREGONING, PATRICK VINK
EXECUTIVE OFFICER
ATLAS VENTURE FUND XI, L.P.
N/A ATLAS VENTURE ASSOCIATES XI, L.P., N/A ATLAS VENTURE ASSOCIATES XI, LLC, KEVIN BITTERMAN, BRUCE BOOTH, DAVID GRAYZEL, JASON RHODES
DIRECTOR
IFM TRE, INC.
GARY D GLICK, VINCENT MILES
EXECUTIVE OFFICER
ATLAS VENTURE OPPORTUNITY FUND I, L.P.
N/A ATLAS VENTURE ASSOCIATES OPPORTUNITY I, L.P., N/A ATLAS VENTURE ASSOCIATES OPPORTUNITY I, LLC, KEVIN BITTERMAN, BRUCE BOOTH, DAVID GRAYZEL, JASON RHODES
DIRECTOR
TRANSLATE BIO, INC.
ANN BARBIER, DANIELLA BECKMAN, PAUL BURGESS, PAULA CLOGHESSY, BRIAN FENTON, JEAN- FRANCOIS FORMELA, BRIAN GALLAGHER, MICHAEL HEARTLEIN, OWEN HUGHES, DANIEL LYNCH, DANIEL S. LYNCH, THOMAS MCCAULEY, ROBERT J. MEYER, ROBERT M. PLENGE, RONALD RENAUD, JR., JOHN R. SCHROER, RICHARD WOOSTER
DIRECTOR
KORRO BIO, INC.
NESSAN BERMINGHAM, OMMER CHOHAN
DIRECTOR
IFM QUATTRO, INC.
SHELLEY CHU, GARY GLICK, JOHN LEONARD
DIRECTOR
IFM CINQUE, INC.
SHELLEY CHU, GARY GLICK, JOHN LEONARD
DIRECTOR
IFM CONTINUA, INC.
SHELLEY CHU, GARY GLICK, JOHN LEONARD
EXECUTIVE OFFICER
ATLAS VENTURE FUND XII, L.P.
N/A ATLAS VENTURE ASSOCIATES XII, L.P., N/A ATLAS VENTURE ASSOCIATES XII, LLC, KEVIN BITTERMAN, BRUCE BOOTH, MICHAEL GLADSTONE, DAVID GRAYZEL, JASON RHODES
DIRECTOR
SCORPION THERAPEUTICS, INC.
JEFFREY ALBERS, PETER JOSEPH CAMPISI, JR., MARK CHAO, SHELLEY CHU, ANDREW FEDDER, KEITH FLAHERTY, ADAM FRIEDMAN, GARY GLICK, ARJUN GOYAL, ERICA JACKSON, OLEG NODELMAN, BRIAN PIPER, SAURABH SAHA, OTELLO STAMPACCHIA, DARRIN STUART, AMANDA VALENTINO
DIRECTOR
SPERO THERAPEUTICS, INC.
CASPER BREUM, MILIND DESHPANDE, STEPHEN GARBACZ, VIKAS GOYAL, REZA HALSE, KAMAL HAMED, SCOTT JACKSON, TAMARA JOSEPH, TIMOTHY KEUTZER, CRISTINA LARKIN, ANKIT MAHADEVIA, DAVID MELNICK, JOHN C. POTTAGE, JR., SATYAVRAT SHUKLA, CYNTHIA SMITH, FRANK E. THOMAS, KATHLEEN TREGONING, PATRICK VINK
EXECUTIVE OFFICER
ATLAS VENTURE OPPORTUNITY FUND II, L.P.
N/A ATLAS VENTURE ASSOCIATES OPPORTUNITY II, L.P., N/A ATLAS VENTURE ASSOCIATES OPPORTUNITY II, LLC, KEVIN BITTERMAN, BRUCE BOOTH, MICHAEL GLADSTONE, DAVID GRAYZEL, JASON RHODES
EXECUTIVE OFFICER
ATLAS VENTURE FUND XIII, L.P.
N/A ATLAS VENTURE ASSOCIATES XIII, L.P., N/A ATLAS VENTURE ASSOCIATES XIII, LLC, KEVIN BITTERMAN, BRUCE BOOTH, MICHAEL GLADSTONE, DAVID GRAYZEL, JASON RHODES
DIRECTOR
AMAGMA, INC.
PHILIP FERNEAU, TILLMAN GERNGROSS, TILLMAN U. GERNGROSS, VISHAL PATEL, AMY SCHULMAN
DIRECTOR
IKENA ONCOLOGY, INC.
DAVID BONITA, IAIN D. DUKES, JEFFREY ECSEDY, OWEN HUGHES, MARIA KOEHLER, MARK MANFREDI, JOTIN MARANGO, SERGIO SANTILLANA, OTELLO STAMPACCHIA, RICHARD WOOSTER, MICHELLE ZHANG
DIRECTOR
ANTARES THERAPEUTICS, INC.
JEFFREY ALBERS, SHELLEY CHU, ANDREW FEDDER, KEITH FLAHERTY, ADAM FRIEDMAN, MENELAS N. PANGALOS, BRIAN PIPER
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
2025-05-15
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2025-05-01 
2024-07-16
D
Link
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Equity 
2024-07-01 
2023-08-18
D
Link
PHARMACEUTICALS 
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] 
DECLINE TO DISCLOSE 
Equity 
2023-08-04 
2022-12-23
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2022-12-12 
2022-03-03
D
Link
VENTURE CAPITAL FUND 
 
NOT APPLICABLE 
 
2022-03-02 
2021-10-01
D
Link
VENTURE CAPITAL FUND 
 
NOT APPLICABLE 
 
2021-09-30 
2021-07-14
D
Link
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Equity 
2021-06-30 
2020-12-07
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2020-11-20 
2020-06-04
D
Link
VENTURE CAPITAL FUND 
 
NOT APPLICABLE 
 
2020-05-20 
2019-12-17
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2019-11-25 
2019-12-17
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2019-11-25 
2019-12-17
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2019-11-25 
2019-06-07
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2019-05-24 
2019-05-10
D
Link
BIOTECHNOLOGY 
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] 
DECLINE TO DISCLOSE 
Equity 
2019-05-03 
2019-01-02
D/A
Link
VENTURE CAPITAL FUND 
 
NOT APPLICABLE 
 
2018-12-07 
2018-08-02
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2018-07-18 
2017-06-30
D
Link
VENTURE CAPITAL FUND 
 
NOT APPLICABLE 
 
2017-06-28 
2017-03-21
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2017-03-07 
2016-06-28
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2016-06-17 
2015-12-22
D
Link
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
Equity 
2015-12-14 
2015-09-03
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2015-08-20 
2014-08-15
D/A
Link
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
Equity 
2013-09-19 
2014-06-26
D/A
Link
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
Equity 
2013-09-19 
2014-04-17
D/A
Link
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
Equity 
2012-07-23 
2013-12-09
D
Link
PHARMACEUTICALS 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Debt 
2013-11-22 
2013-10-02
D
Link
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
Equity 
2013-09-19 
2013-06-17
D
Link
PHARMACEUTICALS 
IN VITRO + IN VIVO DIAGNOSTIC SUBSTANCES [2835] 
DECLINE TO DISCLOSE 
 
2013-06-04 
2013-04-10
D
Link
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
Equity 
2013-03-29 
2013-02-01
D
Link
PHARMACEUTICALS 
IN VITRO + IN VIVO DIAGNOSTIC SUBSTANCES [2835] 
DECLINE TO DISCLOSE 
Equity 
2013-01-25 
2012-12-28
D
Link
PHARMACEUTICALS 
IN VITRO + IN VIVO DIAGNOSTIC SUBSTANCES [2835] 
DECLINE TO DISCLOSE 
Equity 
2012-12-18 
2012-10-31
D
Link
PHARMACEUTICALS 
IN VITRO + IN VIVO DIAGNOSTIC SUBSTANCES [2835] 
DECLINE TO DISCLOSE 
Equity 
2012-10-22 
2012-07-25
D
Link
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
Equity 
2012-07-23 
2012-07-24
D/A
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2011-07-20 
2012-03-19
D
Link
PHARMACEUTICALS 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Equity 
2012-03-02 
2012-03-08
D
Link
PHARMACEUTICALS 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
 
2012-02-22 
2012-01-05
D
Link
PHARMACEUTICALS 
IN VITRO + IN VIVO DIAGNOSTIC SUBSTANCES [2835] 
DECLINE TO DISCLOSE 
Equity 
2011-12-22 
2011-06-17
D
Link
PHARMACEUTICALS 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
 
2011-06-02 
2011-05-04
D/A
Link
PHARMACEUTICALS 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Equity, Debt 
2010-04-01 
2011-01-21
D/A
Link
PHARMACEUTICALS 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Equity, Debt 
2010-04-01 
2010-11-08
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Debt 
2010-10-25 
2010-06-18
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Debt 
2010-06-09 
2010-05-24
D
Link
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
Equity, Debt 
2010-04-01 
2010-05-24
D
Link
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
Equity 
2010-04-01 
2009-10-26
D
Link
PHARMACEUTICALS 
IN VITRO + IN VIVO DIAGNOSTIC SUBSTANCES [2835] 
DECLINE TO DISCLOSE 
Equity 
2009-10-18